Rarity Bioscience

📍 Uppsala, Sweden🗓 Founded 2021👥 18 employees💰 Last funded Sep 2021
Biotechnology🌐 raritybioscience.com
Website LinkedIn
Rarity Bioscience provides ultrasensitive multiplex assays for mutation detecting in blood and other liquid biopsies for research, pharma and clinics. The sensitivity of our precision diagnostics technology enables patient stratification, treatment choice & monitoring, early MRD and relapse detection and post-transplantation follow-up for optimized cancer care. It also enables refined inclusion stratification and monitoring in clinical trials. The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Rarity Bioscience?
Rarity Bioscience has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Rarity Bioscience last raise funding?
The most recent investment in Rarity Bioscience recorded on gritt.io was in September 2021.
When was Rarity Bioscience founded?
Rarity Bioscience was founded in 2021.
What industry is Rarity Bioscience in?
Rarity Bioscience operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Rarity Bioscience based?
Rarity Bioscience is headquartered in Uppsala, Sweden.